Financial Performance - The net profit attributable to shareholders for 2022 was RMB 104,114,179.36, with a distributable profit of RMB 346,243,513.10 as of December 31, 2022[5]. - The company plans to distribute a cash dividend of RMB 2.6 per 10 shares, totaling RMB 21,228,480.00, which represents 20.39% of the net profit for the year[5]. - The company's operating revenue for 2022 was CNY 228.81 million, a decrease of 4.63% compared to CNY 239.92 million in 2021[23]. - Net profit attributable to shareholders increased by 6.93% to CNY 104.11 million in 2022, up from CNY 97.37 million in 2021[23]. - The net cash flow from operating activities was CNY 100.56 million, a decline of 6.39% from CNY 107.42 million in 2021[23]. - The company's total assets at the end of 2022 reached CNY 1.61 billion, an increase of 8.64% from CNY 1.48 billion at the end of 2021[23]. - Basic earnings per share rose to CNY 1.28 in 2022, reflecting a growth of 7.56% from CNY 1.19 in 2021[24]. - The company's total revenue for the year reached ¥228,222,764.00, representing a 62.37% increase compared to the previous year[98]. - The sales revenue from coagulation products increased by 72.19% year-on-year, amounting to ¥131,736,202.93[97]. Research and Development - The company is investing in R&D, allocating 150 million RMB towards the development of new technologies and products[15]. - The R&D expenditure as a percentage of operating revenue increased to 7.40% in 2022, up from 6.34% in 2021[24]. - The company invested ¥16,938,833.60 in R&D in 2022, an increase of 11.40% year-on-year[36]. - The company has 21 ongoing R&D projects and has obtained multiple medical device registration certificates and patents during the reporting period[36]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnostic testing platforms, and holds 32 patents, of which 10 are invention patents[50]. - The company is actively developing new diagnostic products, including lupus anticoagulant testing kits, with several projects in the clinical trial phase[61]. - The company has made significant advancements in the development of monoclonal antibodies for D-Dimer detection, which will improve diagnostic accuracy[73]. Market Expansion and Strategy - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[15]. - Market expansion plans include entering two new international markets by the end of the next fiscal year[15]. - The company is considering strategic acquisitions to enhance its product offerings and market presence[15]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[15]. - The company plans to enhance customer acquisition for coagulation products to stabilize revenue amidst declining demand for other products[98]. - The company is focusing on expanding its market presence through the introduction of new products and technologies, aiming for increased competitiveness in the medical device sector[75]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[15]. - The company aims to reduce operational costs by 8% through efficiency improvements in the supply chain[147]. - The operating cost was ¥86,177,055.03, a decrease of 10.08%, with the main business operating cost at ¥85,870,046.34, down 9.67%[94]. - The total gross margin for the year was 62.37%, with a year-on-year decrease of 4.27%[98]. Governance and Compliance - The company maintains a robust governance structure, ensuring compliance with laws and regulations while protecting shareholder rights[133]. - The company emphasizes transparent communication with investors and stakeholders, ensuring timely and accurate information disclosure[136]. - The company’s governance practices comply with relevant laws and regulations, ensuring the legality and validity of shareholder meeting resolutions[140]. - The company has not faced any major legal or regulatory discrepancies in its governance practices[137]. Environmental and Social Responsibility - The company is committed to sustainable development and environmental protection, implementing practices to reduce waste and promote green initiatives[188]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[193]. - The company operates in compliance with environmental regulations, ensuring that wastewater, noise, and solid waste are properly managed[200]. - The company emphasizes sustainable development while protecting the rights of shareholders, creditors, and employees[190]. Human Resources - The number of R&D personnel increased to 48, representing 17.58% of the total workforce, up from 40 and 15.04% respectively in the previous period[80]. - Total compensation for R&D personnel reached 946.14 million, compared to 809.33 million in the prior period[80]. - The company has a comprehensive compensation policy that includes monthly salaries, year-end bonuses, and various allowances, ensuring internal equity and external competitiveness[176]. - The average salary of core technical personnel was reported at 826.42, indicating a competitive compensation structure within the industry[145].

证券代码：688338 证券简称：赛科希德 公告编号：2023-016 北京赛科希德科技股份有限公司 关于召开2022年度暨2023年第一季度业绩暨现金分 红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 北京赛科希德科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日在上海证券交易所网站（www.sse.com.cn）披露了《北京赛科希德科技股份有 限公司 2022 年年度报告》及《北京赛科希德科技股份有限公司 2023 年第一季度 报告》，为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度 经营成果、财务状况，公司计划于 2023 年 4 月 28 日 上午 10:00-11:00 举行 2022 年度暨 2023 年第一季度业绩暨现金分红说明会，就投资者关心的问题进行 交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company's operating revenue for the first half of 2022 was ¥106,222,413.05, a decrease of 4.04% compared to ¥110,690,541.41 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥47,450,850.29, an increase of 13.72% from ¥41,724,265.86 in the previous year[21]. - The net cash flow from operating activities was ¥33,151,262.89, down 9.99% from ¥36,829,455.81 in the previous year[21]. - The gross margin for the first half of 2022 was reported at 60%, a slight improvement from 58% in the same period last year[1]. - Basic earnings per share for the reporting period increased by 13.73% to CNY 0.58 compared to CNY 0.51 in the same period last year[22]. - The company's operating costs decreased by 8.23% to CNY 41.02 million, primarily due to the decline in operating revenue[81]. - The total revenue for the first half of 2022 reached CNY 94,993,600, with a net profit of CNY 69,431,028, representing a significant increase compared to the previous period[57]. Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on innovative diagnostic technologies[1]. - The total R&D investment for the period was ¥8,133,897.23, a decrease of 2.48% compared to the previous year[50]. - Research and development expenses for the first half of 2022 totaled ¥8,133,897.23, accounting for 7.66% of operating revenue[70]. - The company has established a research and development team dedicated to continuous innovation in the thrombus and hemostasis diagnostic field, ensuring a robust pipeline of new products[43]. - The number of R&D personnel increased to 43, representing 16.35% of the total workforce, compared to 39 and 15.29% respectively in the same period last year[60]. - The company holds 30 patents, including 9 invention patents, and has developed a core technology cluster covering five key areas related to blood rheology and coagulation diagnostics[61]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product portfolio and market reach[1]. - The company is focused on maintaining shareholder confidence through strict adherence to share lock-up commitments[107]. - The company is conducting research on the quantification of low molecular weight heparin, which will aid in drug dosage adjustments for patients[56]. - The company aims to meet the increasing demand for high-end automatic coagulation analyzers in tertiary hospitals[53]. Risks and Challenges - The management highlighted potential risks related to supply chain disruptions, which could impact future performance[1]. - The ongoing COVID-19 pandemic has impacted the company's main business, leading to a significant reduction in diagnostic activities in some regions[67]. - The company faces risks related to reliance on foreign suppliers for key raw materials, which could impact production if supply issues arise[75]. - The company is exposed to intensified market competition in the thrombus and hemostasis market due to the entry of more competitors and improvements in existing competitors' technology and service capabilities[76]. Environmental and Compliance - The company has implemented environmental management standards and procedures to ensure compliance with environmental regulations[94]. - The company’s wastewater treatment facilities recycle cleaning wastewater for toilet flushing, ensuring minimal environmental impact[95]. - The company’s production operations are compliant with national environmental laws, with no administrative penalties for violations during the reporting period[99]. - The company has committed to a stable profit distribution mechanism, detailing conditions and proportions for cash dividends and stock dividends in its profit distribution policy[170]. Shareholder Commitments and Governance - The company confirmed the fulfillment of various commitments made by major shareholders and management, with a focus on share lock-up periods and compliance with regulations[102]. - The company has established a long-term commitment to avoid competition with its major shareholders during their control period[104]. - The company has outlined a commitment to maintain compliance with regulations regarding related party transactions, ensuring transparency and accountability[104]. - The company will ensure that newly appointed non-independent directors and senior management sign a commitment regarding stock price stabilization measures[154]. Investment and Financial Management - The company raised a total of CNY 1,027,744,200.00 from its initial public offering, with a net amount of CNY 924,269,637.22 after deducting issuance costs[187]. - The company has approved the use of up to RMB 730 million of idle raised funds for cash management, ensuring it does not affect project construction and normal operations[191]. - The company has committed to compensating investors for any losses incurred due to unfulfilled commitments[182]. - The company will implement stock price stabilization measures if the average closing price is below the latest audited net asset value per share for 20 consecutive trading days[153].

Financial Performance - The company's operating revenue for Q1 2022 was ¥49,375,230.28, representing a decrease of 2.89% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥18,245,252.74, down 6.20% year-on-year[5]. - The basic and diluted earnings per share were both ¥0.22, reflecting a decline of 8.33%[6]. - Total operating revenue for Q1 2022 was ¥49,375,230.28, a decrease of 2.9% from ¥50,843,046.14 in Q1 2021[17]. - Net profit for Q1 2022 was ¥18,245,252.74, a decline of 6.2% compared to ¥19,451,138.70 in Q1 2021[18]. - Total comprehensive income for Q1 2022 was ¥18,245,252.74, reflecting a decrease from ¥19,451,138.70 in Q1 2021[18]. Cash Flow and Expenses - The net cash flow from operating activities was ¥3,134,398.13, down 51.43% compared to the previous year[5]. - Cash flow from operating activities for Q1 2022 was ¥3,134,398.13, a decrease of 51.4% from ¥6,453,318.56 in Q1 2021[21]. - Cash and cash equivalents are reported at ¥1,301,664,616.24, down from ¥1,322,459,728.04[12]. - Cash and cash equivalents at the end of Q1 2022 were ¥1,293,439,304.66, down from ¥1,268,883,343.77 at the end of Q1 2021[22]. - Research and development expenses totaled ¥3,797,490.64, accounting for 7.69% of operating revenue, a decrease of 0.42 percentage points[6]. - Research and development expenses for Q1 2022 were ¥3,797,490.64, a decrease of 7.9% from ¥4,124,300.79 in Q1 2021[17]. - The company reported a decrease in tax expenses for Q1 2022, totaling ¥3,282,864.18, compared to ¥3,212,740.98 in Q1 2021[18]. - Financial expenses for Q1 2022 showed an improvement, with a net income of -¥6,635,861.10 compared to -¥7,581,711.43 in Q1 2021[17]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,494,380,159.07, an increase of 0.72% from the end of the previous year[6]. - Total current assets as of March 31, 2022, amount to ¥1,379,035,264.41, a slight decrease from ¥1,388,458,729.56 at the end of 2021[13]. - The company's total assets as of March 31, 2022, are ¥1,494,380,159.07, compared to ¥1,483,743,725.61 at the end of 2021[13]. - Total liabilities decreased to ¥55,273,251.88 from ¥62,882,071.16, a reduction of approximately 12.5%[14]. - The retained earnings increased to ¥284,863,824.19 from ¥266,618,571.45, showing a growth of about 6.8%[14]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,308[10]. - The largest shareholder, Wu Shiming, holds 28,298,431 shares, representing 34.66% of total shares[10]. Operational Insights - The company noted that the decrease in operating revenue was partly due to the increased impact of COVID-19 in certain regions[8]. - The company experienced a significant increase in prepayments by 225.08%, attributed to higher advance payments for materials[8]. - The cash flow from investment activities increased significantly by ¥6,804,330 due to increased expenditures on the Daxing base project[8]. - Inventory as of March 31, 2022, is ¥40,727,656.05, up from ¥38,420,659.14, indicating an increase of about 6.0%[13]. - Accounts receivable increased to ¥28,331,387.35 from ¥24,472,934.35, reflecting a growth of approximately 15.3%[12]. - The company has not reported any new product developments or market expansion strategies in the current quarter[12].

Financial Performance - The proposed profit distribution plan for 2021 includes a cash dividend of RMB 2.5 per 10 shares, totaling RMB 20,412,000, which accounts for 20.96% of the net profit attributable to shareholders[5]. - The company has not yet achieved profitability since its listing[4]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[14]. - In 2021, the company's operating revenue reached ¥239,915,362.66, representing a year-on-year increase of 7.88% compared to ¥222,398,393.41 in 2020[22]. - The net profit attributable to shareholders increased by 40.73% to ¥97,368,830.48 in 2021, up from ¥69,188,424.17 in 2020[24]. - The net cash flow from operating activities increased by 48.65% to ¥107,423,198.26 in 2021, up from ¥72,266,743.41 in 2020[24]. - The company achieved operating revenue of ¥239,915,362.66, a year-on-year increase of 7.88%[33]. - The company reported a significant increase in cash inflows from sales and interest income, contributing to the rise in operating cash flow[24]. Risk Management - The company has detailed various operational risks in the report, urging investors to be cautious[4]. - The company has a comprehensive risk factor section in the report for investor reference[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company faces risks related to technological iteration and the long R&D cycle of in vitro diagnostic products, which may impact its competitive position if not addressed[81]. - The company relies on foreign suppliers for key raw materials, which poses risks related to import dependency and supply chain stability[83]. - The company faces risks related to reliance on imported raw materials, which could impact production if supply chain disruptions occur[84]. - The company is exposed to potential price reductions due to stricter government regulations on medical device pricing[87]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on advanced technologies in the healthcare sector[14]. - The R&D expenditure as a percentage of operating revenue increased to 6.34% in 2021, up from 6.01% in 2020[23]. - The company has developed 15 core technologies and holds 29 patents, including 8 invention patents, demonstrating strong independent research and development capabilities[47]. - The company has established a core technology cluster covering instruments, reagents, and consumables, with five major technology categories including blood rheology measurement and coagulation diagnostic testing[52]. - The company is focusing on the integration of automation and motion control technologies in the development of platelet aggregation products for clinical diagnosis[53]. - The company is actively expanding its product offerings and improving its technology through ongoing research and development initiatives[66]. - The company has established a strong brand presence in the thrombus and hemostasis in vitro diagnostic market, with over 9,000 domestic terminal medical institution users[193]. Corporate Governance - The board of directors has confirmed the authenticity and completeness of the annual report[5]. - The company has not disclosed any special arrangements for corporate governance[7]. - The governance structure of the company aligns with the regulatory requirements set forth by the China Securities Regulatory Commission[128]. - The company has established a robust investor relations management system to enhance communication and transparency with investors[130]. - The board of directors is composed of members who strictly adhere to the company's articles of association and relevant laws, ensuring compliance and effective governance[129]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors and regulatory bodies[130]. - The company has maintained independence from its controlling shareholder in business, personnel, assets, and financial matters, ensuring autonomous operational capability[131]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[14]. - International sales revenue grew by 68.09%, enhancing the company's brand influence in regions such as the Middle East, Asia, and South America[35]. - The company has established a nationwide marketing service network, covering 29 provinces and key cities, serving tertiary and secondary hospitals[79]. - The company aims to expand its production capacity through the construction of a new production base and the addition of equipment and personnel[124]. - The marketing strategy includes strengthening the domestic marketing network and targeting large public hospitals and third-party testing institutions[125]. Employee and Operational Management - The company has a structured training program for new employees to ensure quick integration into the team[196]. - The company has implemented a comprehensive training program, including onboarding, skills training, and knowledge sharing, to enhance employee capabilities[169]. - The company has achieved a 100% labor contract signing rate, ensuring compliance with labor laws and protecting employee rights[195]. - The company provides various employee benefits, including paid annual leave, communication subsidies, and travel insurance for employees frequently on business trips[196]. - The company has conducted various training programs in 2021, focusing on new employee onboarding, job skills, and business knowledge[195]. Environmental Responsibility - The company is committed to sustainable development, focusing on environmental protection and social responsibility while promoting green practices in its operations[179]. - The company has implemented appropriate measures for wastewater, noise, and solid waste treatment, ensuring compliance with environmental protection laws and regulations[186]. - The company has taken measures to reduce carbon emissions by improving production processes and conserving energy[190]. - The company has established environmental management standards and procedures, including waste disposal management and wastewater treatment[189]. Shareholder Information - The total number of shares held by directors, supervisors, and senior management at the end of the reporting period was 37,303,483, a decrease of 489,218 shares during the year[135]. - The company has a well-defined cash dividend distribution mechanism, with clear decision-making processes and protection for minority shareholders' rights[174]. - The company has established a long-term effective cash dividend policy to ensure continuity and stability in dividend distribution, protecting the rights of shareholders, especially minority investors[172]. - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 20,412,000, which represents 20.96% of the net profit attributable to shareholders for 2021[173].

Financial Performance - The company's revenue for Q3 2021 was ¥53,462,283.47, representing a year-on-year increase of 2.93%[5] - Net profit attributable to shareholders was ¥25,315,625.17, up 67.52% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses was ¥21,889,090.45, an increase of 44.98% year-on-year[5] - Basic earnings per share were ¥0.31, reflecting a 93.79% increase compared to the previous year[6] - Total operating revenue for the first three quarters of 2021 reached ¥164,152,824.88, an increase of 8.4% compared to ¥151,135,602.87 in the same period of 2020[21] - Net profit for the first three quarters of 2021 was ¥67,039,891.03, up 66.9% from ¥40,158,932.04 in the previous year[22] - Earnings per share for the period was ¥0.82, compared to ¥0.57 in the same period last year, reflecting a 43.9% increase[22] - The company reported a total profit of ¥76,696,181.38 for the first three quarters, an increase of 62.1% from ¥47,335,283.68 in the same period of 2020[22] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date was ¥58,050,438.23, showing a significant increase of 97.07%[5] - Operating cash inflow for Q3 2021 was CNY 214,679,023.96, an increase from CNY 191,503,072.86 in Q3 2020, representing a growth of approximately 12.1%[25] - Net cash flow from operating activities was CNY 58,050,438.23, significantly up from CNY 29,456,685.13 in the same period last year, indicating a year-over-year increase of about 96.5%[25] - Cash outflow from investment activities totaled CNY 1,271,040.70, a decrease from CNY 31,059,154.12 in Q3 2020, reflecting a reduction of approximately 95.9%[26] - Net cash flow from financing activities was negative CNY 35,431,435.32, compared to a positive CNY 912,623,588.23 in Q3 2020, showing a significant decline[26] - The ending balance of cash and cash equivalents was CNY 1,283,998,568.75, up from CNY 1,231,494,688.84 at the end of Q3 2020, marking an increase of about 4.3%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,441,027,266.93, a growth of 2.82% from the end of the previous year[6] - Total assets reached CNY 1.44 billion, an increase from CNY 1.40 billion at the end of 2020[18] - Total liabilities increased to ¥50,494,551.93 from ¥45,312,936.30, marking an increase of 11.9%[19] - Total equity attributable to shareholders rose to ¥1,390,532,715.00 from ¥1,356,152,023.97, an increase of 2.5%[19] - Current liabilities totaled 43,743,257.64, with a significant portion attributed to employee compensation and taxes payable[30] - Non-current liabilities rose to 5,294,926.81, primarily due to lease liabilities of 3,725,248.15[30] Research and Development - Research and development expenses totaled ¥3,546,751.06, accounting for 6.63% of revenue, which is an increase of 0.08 percentage points[6] - Research and development expenses for the first three quarters were ¥11,887,089.91, up from ¥10,203,118.14, indicating a growth of 16.5%[21] - The company obtained 1 new invention patent during the reporting period, and 5 new in vitro diagnostic reagent products completed the registration assessment phase[15] Government Support and Subsidies - The company received government subsidies amounting to ¥4,035,210.62 during the reporting period, contributing to other income[9] Market and Future Plans - The company plans to continue expanding its market presence and investing in new technologies, although detailed figures and timelines were not provided in the report[26] - The company is advancing the construction of its integrated production and R&D project for thrombosis and hemostasis products, having obtained the necessary planning permits[15] Financial Reporting Changes - The company has implemented new leasing standards starting in 2021, which may affect future financial reporting and cash flow management[26] - The earnings report was officially announced on October 27, 2021, by the board of directors[32]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1] - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2021, representing a 15% year-over-year growth[15] - The company's operating revenue for the first half of 2021 increased by 11.59% year-on-year, reaching approximately ¥110.69 million, primarily due to the effective control of the domestic COVID-19 pandemic[22] - The net profit attributable to shareholders for the same period grew by 66.59% year-on-year, amounting to approximately ¥41.72 million, driven by an increase in operating revenue and a reduction in financial expenses[23] - The net cash flow from operating activities surged by 93.87% year-on-year, totaling approximately ¥36.83 million, attributed to higher cash receipts from sales and other operating activities[23] - The company achieved a revenue of 110.69 million yuan in the first half of 2021, representing a year-on-year increase of 11.59%[62] - The net profit attributable to shareholders reached 41.72 million yuan, up 66.59% year-on-year, while the net profit after deducting non-recurring gains and losses was 40.27 million yuan, an increase of 43.06%[63] User Growth - User data indicates a growth in active users by 15% compared to the previous year, reaching a total of 1.5 million active users[1] - User data indicates a growth in active users, with a 20% increase compared to the previous year, reaching 500,000 active users[15] Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2021[1] - The company is expanding its market presence, targeting new regions in Asia, which is anticipated to contribute an additional 5% to overall revenue growth[15] - The company has established a nationwide marketing service network covering 29 provinces and key cities, excluding Tibet, Qinghai, and Hong Kong and Macau[60] Product Development - New product development includes the launch of a next-generation diagnostic kit, projected to increase market share by 10%[1] - New product development includes the launch of a next-generation diagnostic tool, expected to enhance market competitiveness and drive sales growth[15] - The company has completed clinical trials for several new products, including D-Dimer test kits and AT reagent kits, which are expected to enhance its product offerings in the market[52] - The company has developed a core technology cluster covering instruments, reagents, and consumables, with 15 core technologies and 27 patents, including 6 invention patents[31] Research and Development - Research and development expenses have increased by 15%, reflecting the company's commitment to innovation and new technology[1] - The company plans to invest 200 million RMB in R&D for the upcoming year to support innovation and product development[15] - The company's R&D expenditure as a percentage of operating revenue rose to 7.53%, an increase of 0.68 percentage points compared to the previous year[22] - The company has achieved a 22.67% increase in research and development expenses, totaling ¥8,340,338.85, compared to ¥6,799,162.81 in the previous period[47] - The company has 15 ongoing R&D projects, focusing on the development of high-performance fully automated coagulation testing instruments and specialized coagulation detection reagents[63] Strategic Acquisitions - The company has completed a strategic acquisition of a local competitor, which is expected to enhance its product offerings and increase revenue by an estimated RMB 50 million annually[1] - A strategic acquisition of a smaller biotech firm was completed, which is expected to enhance the company's R&D capabilities and product offerings[15] Compliance and Risk Management - The company emphasizes the importance of compliance with regulatory requirements to mitigate risks associated with financial reporting[1] - The company has identified potential risks in supply chain disruptions, which may impact future performance if not addressed[1] - The company faces technology iteration risks in the field of thrombus and hemostasis in vitro diagnostic products due to potential revolutionary changes in technology by competitors[65] - The company relies on foreign suppliers for key raw materials, such as D-Dimer B3 Bulk and FDP Bulk, which poses risks related to import dependency and potential supply chain disruptions[68] Environmental Compliance - The company has maintained compliance with environmental regulations, with no penalties reported during the reporting period[87] - The company operates its in vitro diagnostic reagent production facility in Changping District, Beijing, with environmental impacts including wastewater, noise, and solid waste management[88] - Wastewater from production is treated and reused for toilet flushing, while domestic wastewater is processed at the Changping sewage treatment center[88] Shareholder Commitments - The controlling shareholder, Wu Shiming, has committed to a 36-month lock-up period for shares post-IPO, during which no shares will be transferred or managed by others[97] - The commitments will remain effective as long as the controlling shareholders hold significant influence over the company[118] - The company commits to the accuracy and completeness of its prospectus, bearing legal responsibility for any false statements or omissions[141] Financial Management - The company has established a fundraising management system to ensure that raised funds are used specifically for designated projects[162] - The company will implement stock price stabilization measures if the average closing price over 20 consecutive trading days is below the latest audited net asset value per share[156] - The company will hold a board meeting within 5 trading days to discuss profit distribution or capital reserve conversion plans if stabilization measures are triggered[149]

Financial Performance - Net profit attributable to shareholders was ¥19,451,138.70, representing a significant increase of 451.46% year-on-year[6] - Operating revenue for the period was ¥50,843,046.14, marking a growth of 58.45% compared to the same period last year[6] - Basic earnings per share increased to ¥0.24, up 300% from ¥0.06 in the same period last year[6] - The weighted average return on equity rose to 1.42%, an increase of 0.48 percentage points compared to the previous year[6] - The company reported a net profit of ¥22,664,010.85 for Q1 2021, compared to a net profit of ¥7,796,297.11 in Q1 2020, marking a growth of 190.5%[34] - The total profit for Q1 2021 was ¥22,937,450.63, significantly higher than ¥3,943,656.35 in Q1 2020[36] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 196.98% to ¥19,344,242.74 from ¥6,513,612.94[20] Cash Flow - The net cash flow from operating activities was ¥6,453,318.56, a recovery from a negative cash flow of ¥10,916,233.02 in the previous year[6] - Net cash flow from operating activities improved by ¥17,369,551.58, resulting in a positive cash flow of ¥6,453,318.56 compared to a negative cash flow of -¥10,916,233.02 in the previous year[19] - The cash received from sales and services in Q1 2021 was ¥59,298,647.28, compared to ¥36,684,528.22 in Q1 2020, marking a 62% increase[40] - The company reported a net cash flow from operating activities of ¥6,475,152.93, compared to a negative cash flow of ¥10,917,731.64 in the same period last year[43] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,420,928,668.29, an increase of 1.39% compared to the end of the previous year[6] - Total liabilities stood at ¥94,285,057.85, showing a marginal increase from ¥94,243,107.00 at the end of 2020[30] - The company's equity attributable to shareholders reached ¥1,376,398,663.61, up from ¥1,356,672,782.50 at the end of 2020, representing a growth of 1.9%[31] - The total non-current liabilities amounted to ¥5,007,911.16, a significant increase from ¥1,569,678.66 at the end of 2020[30] - The company reported a total liability of CNY 45,312,936.30, with a total equity of CNY 1,356,152,023.97 as of the end of Q1 2021[47] Research and Development - R&D expenses grew by 38.71% to ¥4,124,300.79, attributed to higher personnel costs and product registration fees[17] - Research and development expenses for Q1 2021 were ¥4,124,300.79, an increase of 38.5% from ¥2,973,329.57 in Q1 2020[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,753[11] - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[11] Financial Strategy and Accounting Changes - The company implemented revised accounting standards for leases, resulting in the recognition of right-of-use assets and lease liabilities[14] - The company has implemented new leasing standards starting from 2021, affecting the financial statements[44] - The company has opted for a simplified approach in implementing the new lease standards, without retrospective adjustments to prior periods[52]

Financial Performance - The proposed profit distribution plan for 2020 includes a cash dividend of RMB 4 per 10 shares, totaling RMB 32,659,200, which accounts for 47.20% of the net profit attributable to shareholders[6]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 15% year-over-year growth[16]. - In 2020, the company's operating revenue decreased by 3.12% year-on-year to CNY 222,398,393.41, primarily due to the impact of the COVID-19 pandemic on routine testing volumes in domestic medical institutions[26]. - The net profit attributable to shareholders decreased by 2.61% year-on-year to CNY 69,188,424.17, influenced by a donation of CNY 4,978,500 to support medical institutions during the pandemic[26]. - The company reported a total revenue of 82,811,600.00 RMB, with a net profit of 12,972,626.60 RMB, indicating a significant growth in financial performance compared to the previous year[70]. - The company achieved operating revenue of RMB 222.40 million, a year-on-year decrease of 3.12%, and a net profit attributable to shareholders of RMB 69.19 million, a decrease of 2.61%[84]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% year-over-year growth[155]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $1.875 billion[155]. Risk Management - The company has detailed various operational risks and corresponding countermeasures in the report, emphasizing the importance of risk management[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a substantive commitment to investors[7]. - The company faces risks related to potential technological changes in the thrombosis and hemostasis diagnostics market, which could impact existing products[89]. - The company may experience adverse effects on its operating performance if regional distributors fail to meet sales targets or if cooperation is disrupted[97]. - The company is exposed to foreign exchange risks due to sales and procurement in foreign currencies, which may impact operating performance[99]. - The company faces risks due to a single product structure and limited product registration certificates, which may not meet future market demands[96]. Governance and Compliance - The audit report issued by the accounting firm is a standard unqualified opinion, ensuring the accuracy of the financial statements[5]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity of the annual report[11]. - The company has a comprehensive governance structure in place, ensuring accountability and transparency in its operations[9]. - The company is committed to maintaining the integrity and completeness of its financial reporting, as stated by the management team[6]. - The company has established a structured profit distribution system in place, including specific arrangements for cash dividends[145]. - The company will prioritize transparency and fairness in all related party transactions to safeguard shareholder interests[158]. Research and Development - The R&D expenditure accounted for 6.01% of operating revenue, slightly down from 6.04% in 2019[25]. - The company has established a core technology cluster in the field of thrombus and hemostasis in vitro diagnostics, covering five major technology categories[36]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnostic testing platforms, and holds 26 patents, of which 5 are invention patents[43]. - The company is focusing on the development of new technologies that improve the sensitivity and speed of plasma viscosity detection, which is crucial for clinical applications[48]. - The company is actively pursuing the commercialization of its D-dimer and FDP antibody products, which are expected to replace imported materials upon successful development[50]. - The company has a robust pipeline of research projects focused on thrombus and hemostasis diagnostics, leveraging its core technology platforms to expand its product line[76]. - The company plans to invest raised funds in production base construction and R&D center development to mitigate dilution of immediate returns[177]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[16]. - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 150 million RMB in revenue by the end of 2021[16]. - The company is focusing on the development of high-performance fully automated coagulation testing instruments and specialized reagents to meet market trends[86]. - The company has established a nationwide marketing service network covering 29 provinces and key cities, excluding Tibet, Qinghai, and Hong Kong and Macau[79]. - The company has developed a competitive advantage in the domestic market by providing high-cost performance testing systems, successfully replacing imported products in secondary hospitals and below[78]. Shareholder Commitments - The controlling shareholder has committed to not transferring shares for 36 months post-IPO[148]. - The commitments outlined will remain effective throughout the company's listing period and until the controlling shareholder is no longer associated with the company[158]. - The controlling shareholder will notify the company of any competitive opportunities that may arise, ensuring they are offered to the company first[157]. - The company will adhere to all relevant regulations and internal rules regarding related party transactions to maintain compliance and protect shareholder rights[158]. - The company has a three-year shareholder dividend return plan post-IPO, which will be strictly followed[182]. Financial Position - The company's total assets at the end of 2020 reached CNY 1,401,464,960.27, an increase of 228.45% compared to the beginning of the year[26]. - The net assets attributable to shareholders increased by 261.94% year-on-year to CNY 1,356,152,023.97, bolstered by net proceeds of CNY 92,426,960 from the IPO[26]. - The company's total net profit attributable to shareholders for 2020 was RMB 69,188,424.17[146]. - The company’s cash dividend distribution plan is subject to approval at the annual general meeting[145]. Operational Efficiency - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[16]. - The company is investing 100 million RMB in new technology to improve production efficiency, aiming for a 30% reduction in operational costs[16]. - The company plans to implement cost-cutting measures aimed at reducing operational expenses by 5% over the next year[151]. - The company is focused on optimizing product structure and expanding overall scale to ensure sustainable development[178].

Financial Performance - Operating revenue for the year-to-date was ¥50,843,046.14, representing a 58.45% increase year-on-year[6]. - Net profit attributable to shareholders was ¥19,451,138.70, a significant increase of 451.46% compared to the same period last year[6]. - Basic and diluted earnings per share were both ¥0.24, reflecting a 300% increase year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥19,344,242.74, an increase of 196.98% year-on-year[6]. - The company reported a total comprehensive income of ¥19,451,138.70 for Q1 2021, compared to ¥3,527,198.52 in Q1 2020, highlighting strong financial performance[34]. - The net profit for Q1 2021 reached ¥19,725,881.11, a significant increase from ¥3,352,107.92 in Q1 2020, marking a growth of approximately 487%[35]. - The operating profit for Q1 2021 was ¥22,937,581.80, compared to ¥7,562,842.98 in Q1 2020, indicating a year-over-year increase of about 203%[35]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,420,928,668.29, an increase of 1.39% compared to the end of the previous year[6]. - The company’s total liabilities decreased by 58.74% in accounts receivable financing, down to ¥502,137.90, mainly due to the maturity of bank acceptance bills[14]. - Total liabilities were ¥45,325,505.62, showing a slight increase from ¥45,312,936.30 at the end of 2020[25]. - The total current assets decreased by 153,701.84 RMB, totaling 1,327,774,197.54 RMB[44]. - The company reported a total equity of 1,356,152,023.97 RMB, unchanged from the previous year[46]. - Total liabilities reached $94,243,107.00, reflecting a decrease of $6,085,906.30[50]. Cash Flow - Net cash flow from operating activities was ¥5,615,737.00, a recovery from a negative cash flow of ¥10,916,233.02 in the previous year[6]. - The company reported a net cash flow from operating activities of ¥5,615,737.00 in Q1 2021, a turnaround from a negative cash flow of ¥10,916,233.02 in Q1 2020[39]. - The cash inflow from operating activities totaled ¥63,950,201.16 in Q1 2021, compared to ¥39,378,594.13 in Q1 2020, showing improved operational efficiency[39]. - The net cash flow from financing activities was -424,528.30 RMB, indicating a cash outflow[43]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,753[11]. - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[11]. Expenses - The cost of goods sold increased by 45.12%, amounting to ¥19,507,128.16, driven by the rise in operating revenue[15]. - Research and development expenses increased by 38.71% to ¥4,124,300.79, reflecting higher personnel costs and product registration fees[15]. - The company reported a 394.33% increase in income tax expenses, totaling ¥3,212,740.98, due to higher operating profits[16]. - The company’s management expenses rose by 35.10% to ¥3,019,415.55, driven by an increase in personnel and intermediary fees[16]. - The company incurred financial expenses of -¥7,344,804.98 in Q1 2021, compared to -¥2,321,449.34 in Q1 2020, indicating a change in financial strategy[35]. Government Subsidies - The company received government subsidies amounting to ¥125,909.09, which are closely related to its normal business operations[10]. Accounting Changes - The company adopted a new leasing standard starting January 1, 2021, resulting in an increase of right-of-use assets by 6,239,608.14 RMB and lease liabilities by 6,085,906.30 RMB[47]. - The company adopted the revised Accounting Standards for Leases starting January 1, 2021, resulting in an increase of $6,239,608.14 in right-of-use assets[51].